Report Package: Immunotherapeutics Targeting MAGE-A, NY-ESO-1, hTERT, WT1, PRAME and Survivin
Delivery costs do not apply or are included.
Ask a question about this product
Report Package: Immunotherapeutics Targeting MAGE-A, NY-ESO-1, hTERT, WT1, PRAME and Survivin
Intracellular cancer targets are estimated to be 3-4 times more frequent than surface protein targets. However, these intracellular cancer targets are not accessible to traditional monoclonal antibody or chimeric antigen receptor (CAR) T-cell therapy. The six reports of this package are covering immunotherapeutics against six important intracellular cancer targets:
- Melanoma-associated antigen A: MAGE-A
- New York esophageal squamous cell carcinoma-1: NY-ESO-1
- Human telomerase reverse transcriptase: hTERT
- Wilms‘ tumor 1: WT1
- Preferentially expressed antigen in melanoma: PRAME
- Survivin
This report package includes six Competitor Analysis reports covering immunotherapeutics directed to six different important cancer targets. The original reports were published in May and June 2018, respectively:
- Competitor Analysis: MAGE-A-Targeted Immunotherapy
- Competitor Analysis: NY-ESO-1-Targeted Immunotherapy
- Competitor Analysis: hTERT-Targeted Immunotherapy
- Competitor Analysis: WT1-Targeted Immunotherapy
- Competitor Analysis: PRAME-Targeted Immunotherapy
- Competitor Analysis: Survivin-Targeted Immunotherapy
Detailed report descriptions and tables of contents from the reports can be found on the respective product page. The reports can be acquired separately or as a package with a 40% discount on list prices.
About Competitor Analysis Series:
The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.
Report Package: Immunotherapeutics Targeting MAGE-A, NY-ESO-1, hTERT, WT1, PRAME and Survivin
Tables of Contents
Competitor Analysis: MAGE-A-Targeted Immunotherapy
1) MAGE-A-Targeted Immunotherapy:
- MAGE-A1
- MAGE-A3
- MAGE-A4
- MAGE-A6
- MAGE-A10
- MAGE-A12
2) Corporate & Institutional MAGE-A Immunotherapy R&D Pipelines
Competitor Analysis: NY-ESO-1-Targeted Immunotherapy
1) NY-ESO-1-Targeted Immunotherapy
- NY-ESO-1 Selective Cancer Vaccines
- NY-ESO-1 Specific, Multi-Target Cancer Vaccines
- NY-ESO-1 Selective Adoptive Cell Therapy
- NY-ESO-1 Specific, Multi-Target Adoptive Cell Therapy
- NY-ESO-1 Selective Recombinant Antibodies & Proteins
2) Corporate & Institutional NY-ESO-1 Immunotherapy R&D Pipelines
Competitor Analysis: hTERT-Targeted Immunotherapy
1) hTERT-Targeted Immunotherapy
- hTERT-Selective Cancer Vaccines
- hTERT-Specific, Multi-Target Cancer Vaccines
- hTERT-Targeted Adoptive Cell Therapy
- Other hTERT-Targeted Immunotherapies
2) Corporate & Institutional hTERT Immunotherapy R&D Pipelines
Competitor Analysis: WT1-Targeted Immunotherapy
1) WT1-Targeted Immunotherapy
- Selective WT1-Targeted Vaccines
- WT1-Specific, Multi-Target Vaccines
- WT1-Selective Adoptive Cell Therapy
- WT1-Specific, Multi-Target Adoptive Cell Therapy
- WT1-Targeted Antibodies
2) Corporate & Institutional WT1 Immunotherapy R&D Pipelines
Competitor Analysis: PRAME-Targeted Immunotherapy
1) PRAME-Targeted Immunotherapy
- PRAME-Targeted Selective and Multi-Antigen Cancer Vaccines
- PRAME-Selective Cellular & Recombinant Immunotherapies
- PRAME-Specific, Multi-Target Adoptive Cell Therapy
2) Corporate & Insitutional PRAME Immunotherapy R&D Pipelines
Competitor Analysis: Survivin-Targeted Immunotherapy
1) Survivin-Targeted Immunotherapy
- Survivin-Selective Cancer Vaccines
- Survivin-Specific, Multi-Antigen Cancer Vaccines
- Survivin-Selective Adoptive T-Cell Therapy & Oncolytic Viral Immunotherapy
- Survivin-Specific, Multi-Target Adoptive T-Cell Therapy
2) Corporate Survivin Immunotherapy R&D Pipelines